BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azaciditine) in China under a license from Celgene Corporation.
BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop first in class, multi-mechanistic immunotherapy that can defeat cancer and prevent relapse and recurrence in multiple tumor types.
Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.
BioEclipse Therapeutics™ is preparing to commence an open Phase I clinical trial in 2020 with an intravenously-delivered, targeted biotherapy in patients with resistant and recurring solid tumors.
Brenus Pharma is a French biotech company targeting high unmet medical needs in oncology with the objective to become leader in allogenic cell-based immunotherapy.
Its management team skilled in cell-ATMP manufacturing and oncology business and supported by academics developed and patented both technology STC and first therapeutic candidate STC-1010.
Technology of Stimulated Tumor Cells is based on the capability of combined master-cell banks to overexpress resistance factors under conditions mimicking treatment and chemical tagging of TAA/TSA to boost immunogenicity. STC is scalable and secured on time and costs of production. Original mode of action is by-pass of chemoresistance, by-pass of immunotolerance and impact on tumor micro-environment through induction of immune response.
Carisma Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor macrophages (CAR-M) for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Our work offers more than information; it can inspire hope in patients, families, friends, physicians, and caregivers.
Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
It's lead compound, NBTXR3, is a first-in-class product designed to enhance the effect of radiation within tumor cells when activated by Radiotherapy. NBTXR3 is being explored in several indications both as a single agent and combination.
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi (“INTASYL™”) therapeutic platform. Our efforts are focused on silencing tumor-induced suppression of the immune system through our proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities.
Triumvira Immunologics, Inc. (Triumvira), is a private, immuno-therapy biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, in particular solid tumors. Triumvira is developing differentiated autlogous and allogenic cell therapy approaches in tumors with high unmet needs.
Unlike chimeric antigen receptor (CAR) and other engineered T cell receptor (TCR) therapies, the company’s proprietary T Cell Antigen Coupler (TAC) technology functions by a distinct mechanism that involves (i) cancer cell recognition that is independent of the major histocompatibility complex (MHC), and (ii) activates T cells via the recruitment of the entire natural T cell receptor. This results in a controlled, tumor-specific response, providing a selective advantage for developing safer and more efficacious cell therapies for a broad range of patients with solid tumor or liquid malignancies.
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens.
Virica Biotech Inc. is a Canadian company, based in Ottawa, that specializes in the development of proprietary viral sensitizer compounds (VSe) as well as a proprietary oncolytic viral therapy.
The VSe platform to date consists of over 100 small molecules that enhance the manufacturing and efficacy of viruses for downstream applications such as gene therapy, oncolytic viral therapy, vaccines, and cell-therapy. The company currently commercializes an off-the-shelf formulation for lentiviral platforms which has shown to increase yields by 7x. Several other similar products are in development for other viral vector platforms.
Additionally, Virica is developing a proprietary oncolytic viral therapy platform for solid tumor injections based on a VSV + relevant transgene platform in combination with Virica's VSe technology.